Bioimpedance monitoring is moving from physiology labs to heart failure care pathways
Heart failure remains a disease of recurring congestion, where small shifts in total body fluid can precede dyspnea, weight gain, pleural effusion, and hospitalization. In that setting, bioimpedance has obvious appeal: impedance changes can reflect thoracic fluid shifts before a patient feels dramatically worse, giving clinicians a chance to act earlier than they can with symptoms alone. The review mapped how this technology is now being paired with artificial intelligence and clinical decision-support systems to sharpen surveillance for decompensation, readmission, and fluid overload.
This was a scoping review conducted under PRISMA-ScR guidance with searches across Scopus, IEEE Xplore, PubMed, and Embase. The final search date was August 2, 2026. Ten studies met inclusion criteria, a small evidence base but one that already spans implanted devices, wearables, and other non-invasive systems. The measurement strategies were not uniform: some studies used intrathoracic impedance, others thoracic bioimpedance, and others whole-body bioimpedance analysis.
A fragmented technology base often slows adoption. Here, it also reveals where the field is still trying to standardize the signal.
What the included studies tried to predict
The clinical targets were practical and closely tied to everyday heart failure management. AI models were directed toward heart failure decompensation, fluid accumulation, pleural effusion, and the risk of hospitalization or readmission. The CDSS applications were somewhat different in tone and function: they primarily delivered risk information, alerts, or structured support for clinical decisions rather than operating as stand-alone prediction engines.
That split matters because bioimpedance is not the endpoint; it is the sensor input. A raw impedance trend can be clinically suggestive, but the bedside value comes from translating those signals into something usable in real time. AI may help by filtering noise, integrating longitudinal patterns, and identifying changes that do not look dramatic in isolation but become meaningful when placed into a patient-specific trajectory. In heart failure, where congestion is often a moving target rather than a binary state, pattern recognition has real appeal.
The evidence map suggests a field that is no longer confined to proof-of-concept work. Even so, the small number of studies means the current signal is more directional than definitive.
Why fluid-status prediction is a natural use case for AI
The biological logic is straightforward. Congestion is central to heart failure progression, and volume overload often evolves gradually before it becomes clinically obvious. Bioimpedance devices measure electrical properties that change as fluid content changes, which makes them attractive for surveillance of pulmonary or systemic congestion. When those data streams are fed into machine-learning systems, the promise is not only earlier detection but also a more individualized threshold for concern.
This is where AI becomes more than a statistical accessory. Human clinicians can recognize overt edema or a clear weight jump, but they cannot manually integrate every impedance trend, symptom report, and prior hospitalization pattern with perfect consistency. Algorithms are better suited to handling that kind of multidimensional stream, especially when the goal is to flag patients who are drifting toward decompensation before they cross a crisis threshold. The review indicates that investigators are already using this logic to target hospitalization risk, pleural effusion, and readmission.
The review also shows how broad the technical ecosystem has become. Implanted sensors, wearables, and other non-invasive systems are all represented, which suggests no single device class has yet become dominant. Such heterogeneity is useful for innovation, but it also complicates cross-study comparison and makes it difficult to know whether performance differences come from the sensor, the algorithm, or the patient population.
Decision support is being used as a bridge between signal and action
Not every system in the review relied on machine learning alone. Two studies incorporated a clinical decision-support system, and two used both AI and CDSS. Those platforms mainly offered alerts, risk information, or structured decision support, which is clinically important because the real challenge in heart failure is not simply detecting fluid accumulation. The challenge is deciding when to intervene, how aggressively to adjust therapy, and which patients need urgent reassessment versus closer outpatient follow-up.
CDSS tools are attractive because they can translate biomarker-like data into a workflow clinicians can actually use. A rising impedance signal may trigger medication review, closer weight monitoring, or a prompt for symptom reassessment. In a disease where congestion can escalate quickly and where readmission risk is high, the timing of that prompt can change the entire trajectory of care. The review does not claim that these systems are already proven to reduce admissions, but it makes clear that the technical scaffolding for that next step is already in place.
The evidence base is promising, but still early and uneven
Ten studies are enough to show momentum, not enough to settle practice. The review does not present a mature outcome literature with uniform endpoints, consistent sensing methods, or a single dominant implementation strategy. Instead, it captures a field in transition, with multiple sensor types, different analytic methods, and distinct clinical use cases converging on the same problem: how to recognize congestion early enough to prevent decompensation.
That heterogeneity limits direct comparison, yet it also mirrors the complexity of heart failure itself. Congestion does not announce itself in the same way in every patient, and one monitoring strategy may work better in a chronically congested phenotype than in a patient whose main problem is rapid episodic fluid retention. The best future studies will likely need to separate those populations rather than assume one model fits all.
In practical terms, the review points toward a future in which bioimpedance is not a passive monitoring tool but part of a larger decision chain. A sensor that detects fluid shifts, an algorithm that interprets the trend, and a decision-support platform that tells the clinician what to do next could together create a more responsive heart failure care model. The evidence gathered here suggests that this integration is already underway, even if the clinical validation is still incomplete.
What still needs to be proven before routine use
Several questions remain open. Performance across implanted and wearable platforms may differ, and the review does not provide a basis for declaring one approach superior. The same is true for clinical impact: prediction of decompensation is valuable only if it translates into better treatment decisions, fewer admissions, or less severe episodes of congestion. The field also needs clearer information on calibration, alert burden, and how often these systems generate actionable findings rather than noise.
For now, the most defensible conclusion is narrow and clinically concrete. Bioimpedance paired with AI or decision support is an active and expanding strategy for heart failure volume-status management, but the current evidence is still a map of possibilities rather than a settled standard of care. The next studies will need to show not only that these systems can detect worsening congestion, but that they can do so reliably enough to change what happens at the bedside.